ABCG2 and neoplasm: Like topotecan, the topoisomerase I inhibitor SN38 is an ABCG2 substrate [29], [30], and therefore drug-naïve tumors with ABCG2-positive nests of tumor cells should quickly acquire resistance during irinotecan treatment.